Kommentar: ALK-Abelló har opjusteret forventningerne til 2020, men det bemærkes at opjustering kommer på baggrund af udskudte projekter i deres forsknings- og udviklingsdivision. Dette er en engangseffekt, og skal derfor ikke forventes fremadrettet i 2021.
Opdateret forventninger til 2020:
In light of the results for the first half of 2020 and the ongoing effects of COVID-19, ALK is updating its financial outlook for 2020 and upgrading EBITDA and cash flow forecasts. ALK’s working assumption is that, during H2, the majority of markets will recover so that allergy patients are once again able and willing to visit healthcare professionals. ALK also expects that market conditions in the USA are likely to remain challenging over the short term. As a result:
- Revenue growth is currently tracking towards the lower end of the guided range of 8-12% due to the US market conditions. However, a stronger than expected recovery in the USA, or elsewhere, cannot be ruled out at this stage. Planned product discontinuation is still reducing growth by 4 p.p.
- Operating profit (EBITDA) is now expected to be DKK 300-350 million (previously 200-300).
- Free cash flow is now expected to be negative at approximately DKK 200 million (previously negative ~300).
